Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2023 - Issue 3

Pharmacokinetics of Amikacin in Eye Media Using Various Drugs Download PDF


, , , , ,
Abstract

In the treatment of eye diseases caused by various bacteria, it is extremely important to achieve a therapeutic dose of the drug in the affected organ on time. Otherwise, antibiotic resistance may develop. However, the situation is complicated by the fact that the permeability of the blood-ocular barrier of the inflamed eye drops significantly, and the therapeutic dose of most antibiotics is reached only within 3-4 days of treatment. This article uses the example of laboratory animals (rabbits) to study ways to increase the permeability of the blood-ocular barrier. To do this, individuals who have been injected with a strain of microorganisms Staphylococcus aureus are treated with the antibiotic amikacin. The effect of drugs Cerebrolysin, nicotinic acid, and Selenpropionics on the rate of penetration of the antibiotic into the affected organ is being studied. The course of the disease and the general well-being of rabbits are monitored, and the biochemical and hematological parameters of blood are analyzed. In addition, on the first and fifth day of the course of the disease, the concentration of amikacin in biological fluids was determined: in the blood serum and the intraocular fluid.

Cite this article
Vancouver
Bersanova MK, Batkhieva LM, Baramiya TE, Birkaya DG, Belokobylskaya EV, Saidova ZT. Pharmacokinetics of Amikacin in Eye Media Using Various Drugs. Pharmacophore. 2023;14(3):107-13. https://doi.org/10.51847/qZS08gqJvC
APA
Bersanova, M. K., Batkhieva, L. M., Baramiya, T. E., Birkaya, D. G., Belokobylskaya, E. V., & Saidova, Z. T. (2023). Pharmacokinetics of Amikacin in Eye Media Using Various Drugs. Pharmacophore, 14(3), 107-113. https://doi.org/10.51847/qZS08gqJvC

QR code:

Short Link:
Views: 80

Downloads: 39
Quick Access

Pharmacophore
ISSN: 2229-5402

Pharmacophore
© 2024 All rights reserved
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.